Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 November, 2018 06:02 IST
Zydus receives final approval from USFDA for Zolmitriptan tablets
Source: IRIS | 12 Jul, 2018, 10.37AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the USFDA to market Zolmitriptan Tablets, 2.5 mg and 5 mg. It is used to treat migraines. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting and sensitivity to light/sound). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

In line with this, the group now has 203 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 2.55, or 0.69%, to trade at Rs 368.95. The total volume of shares traded was 37,256 at the BSE (10.24 a.m., Thursday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Welspun Corp bags large order for supply of pipes for oil & gas project - 16-Nov-2018 15:36
Bharat Electronics pays Rs 644.1mn dividend to Govt of India - 16-Nov-2018 10:09
Shilpa Medicare gets tentative nod for Dimethyl Fumarate capsules - 16-Nov-2018 10:01
NIIT Tech partners with R3 to build solutions on Corda platform - 16-Nov-2018 09:42
Glenmark Pharma gets USFDA approval for Teriflunomide tablets - 16-Nov-2018 09:36
Steel Strips Wheels bags export order for EU caravan market - 15-Nov-2018 15:33
Lupin receives USFDA approval for Decitabine for injection - 15-Nov-2018 12:00
Zydus Cadila receives USFDA nod for Arsenic Trioxide injection - 15-Nov-2018 10:11
ICICI Bank raises retail term-deposit interest rates by upto 25bps - 15-Nov-2018 09:55
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer